Literature DB >> 11408604

Dopamine D(4) and D(2L) Receptor Stimulation of the Mitogen-Activated Protein Kinase Pathway Is Dependent on trans-Activation of the Platelet-Derived Growth Factor Receptor.

J N Oak1, N Lavine, H H Van Tol.   

Abstract

The ability of dopamine D(4) and D(2) receptors to activate extracellular signal-regulated kinases (ERKs) 1 and 2 was compared using Chinese hamster ovary (CHO-K1) cells transfected with D(4.2), D(4.4), D(4.7), and D(2L) receptors. Dopamine stimulation of D(4) or D(2L) receptors produced a transient, dose-dependent increase in ERK1/2 activity. Receptor-specific activation of the ERK mitogen-activated protein kinase (MAPK) pathway was confirmed using the D(2)-like receptor-selective agonist quinpirole, whereas the specific antagonist haloperidol blocked activation. MAPK stimulation was dependent on a pertussis-toxin-sensitive G protein (G(i/o)). trans-Activation of the platelet-derived growth factor (PDGF) receptor was an essential step in D(4) and D(2L) receptor-induced MAPK activation. PDGF receptor-selective tyrosine kinase inhibitors tyrphostin A9 and AG1295 abolished or significantly inhibited ERK1/2 activation by D(4) and D(2L) receptors. Dopamine stimulation of the D(4) receptor also produced a rapid increase in tyrosine phosphorylation of the PDGF receptor-beta. The Src-family tyrosine kinase inhibitor PP2 blocked MAPK activation by dopamine; however, this drug was also found to inhibit PDGF-BB-stimulated ERK activity and autophosphorylation of the PDGF receptor-beta. Downstream signaling pathways support the involvement of a receptor tyrosine kinase. The phosphoinositide 3-kinase inhibitors wortmannin and LY294002, protein kinase C inhibitors GF109203X and Calphostin C, dominant-negative RasN17, and the MEK inhibitor PD98059 significantly attenuated or abolished activation of MAPK by dopamine D(4) and D(2L) receptors. Our results indicate that D(4) and D(2L) receptors activate the ERK kinase cascade by first mobilizing signaling by the PDGF receptor, followed by the subsequent activation of ERK1/2 by pathways associated with this receptor tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408604     DOI: 10.1124/mol.60.1.92

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

Review 1.  Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop.

Authors:  Kohji Fukunaga; Norifumi Shioda
Journal:  Mol Neurobiol       Date:  2011-12-20       Impact factor: 5.590

2.  Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Authors:  Geneviève Oligny-Longpré; Maithé Corbani; Joris Zhou; Mireille Hogue; Gilles Guillon; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

3.  Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1.

Authors:  Fuwang Peng; Honghong Yao; Xuetao Bai; Xuhui Zhu; Benjamin C Reiner; Michael Beazely; Keiko Funa; Huangui Xiong; Shilpa Buch
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 4.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

5.  Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Authors:  Peter Heusler; Liesbeth Bruins Slot; Isabelle Rauly-Lestienne; Christiane Palmier; Stéphanie Tardif; Amélie Tourette; Marie-Christine Ailhaud; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-06       Impact factor: 3.000

6.  Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2016-05-11       Impact factor: 9.306

7.  Dopamine D₄ receptor activation controls circadian timing of the adenylyl cyclase 1/cyclic AMP signaling system in mouse retina.

Authors:  Chad R Jackson; Shyam S Chaurasia; Christopher K Hwang; P Michael Iuvone
Journal:  Eur J Neurosci       Date:  2011-06-16       Impact factor: 3.386

8.  Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Authors:  Tarsis F Brust; Michael P Hayes; David L Roman; Kevin D Burris; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2014-12-24       Impact factor: 4.030

9.  Circadian rhythm of contrast sensitivity is regulated by a dopamine-neuronal PAS-domain protein 2-adenylyl cyclase 1 signaling pathway in retinal ganglion cells.

Authors:  Christopher K Hwang; Shyam S Chaurasia; Chad R Jackson; Guy C-K Chan; Daniel R Storm; P Michael Iuvone
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

Review 10.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.